Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Inherent or acquired resistance to sotorasib poses a substantialt challenge for NSCLC treatment. Here, we demonstrate that acquired resistance to sotorasib in isogenic cells correlated with increased expression of integrin β4 (ITGB4), a component of the focal adhesion complex. Silencing ITGB4 in tolerant cells improved sotorasib sensitivity, while overexpressing ITGB4 enhanced tolerance to sotorasib by supporting AKT-mTOR bypass signaling. Chronic treatment with sotorasib induced WNT expression and activated the WNT/β-catenin signaling pathway. Thus, silencing both ITGB4 and β-catenin significantly improved sotorasib sensitivity in tolerant, acquired, and inherently resistant cells. In addition, the proteasome inhibitor carfilzomib (CFZ) exhibited synergism with sotorasib by down-regulating ITGB4 and β-catenin expression. Furthermore, adagrasib phenocopies the combination effect of sotorasib and CFZ by suppressing KRAS activity and inhibiting cell cycle progression in inherently resistant cells. Overall, our findings unveil previously unrecognized nongenetic mechanisms underlying resistance to sotorasib and propose a promising treatment strategy to overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Fig. 7. In vivo models confirm the sensitivity of cells to KRAS G12C inhibitors and CFZ combination treatment. Mice xenografts were created using SW1573 cells to determine the antitumor effects of sotorasib, adagrasib, and CFZ and their combinations in vivo. (A) Schematic of in vivo study. (B and C) Changes in the tumor area changes (mm2) of xenografts with respect to sotorasib (2.5 or 5 mg/kg) or CFZ (1 mg/kg) single treatments and drug combination treatments [sotorasib (2.5 mg/kg) + CFZ (1 or 5 mg/kg) + CFZ (1 mg/kg)]. Statistical significance was calculated using one-way ANOVA. n = 5. ****P < 0.0001. (D) Survival probability of the mice harboring SW1573 cell line–derived xenografts. The combination treatment of sotorasib (2.5 mg/kg) + CFZ (1 or 5 mg/kg) + CFZ (1 mg/kg) has the highest median survival compared to single treatments. (E and F) Changes in the tumor area (mm2) of H23 cell line–derived xenografts with respect to sotorasib (5 mg/kg) or CFZ (1 mg/kg) single treatments or combination treatments [sotorasib (5 mg/kg) + CFZ (1 mg/kg)]. Survival probability of the mice harboring H23 cell line–derived xenografts. Statistical significance was calculated using one-way ANOVA. n = 5. ****P < 0.0001. (G and H). Changes in the tumor area (mm2) of H23 isogenic resistant cell line–derived xenografts and survival. The combination treatment of sotorasib (5 mg/kg) + CFZ (1 mg/kg) has the highest median survival compared to the single drug. Statistical significance was calculated using one-way ANOVA. n = 5. ****P < 0.0001.](https://figures.cochat.ai/paper-figures/b45cf71194ad4aa08505ac405e72a472/acquired-resistance-to-kras-g12c-small-molecule-inhibitors-via-genetic-figure-7.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent paper demonstrated nongenetic mechanisms of resistance to AMG510 involving integrin β4 and found that AMG510-resistant lung cancer cell lines (H358, H23, and SW1573) remain sensitive to MRTX849 (57).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent study by Mohanty et al. suggested that the focal adhesion complex and the Wnt/ b -catenin signaling pathway play important roles in mediating the acquired resistance of KRAS G12C inhibitors, which could be alleviated by carfilzomib. 30”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mohanty et al. 30 recently found that proteasome inhibitor exhibited synergism with sotorasib by downregulating ITGB4 and b -catenin expression.”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“a recent study has also found that carfilzomib exhibited synergism with sotorasib in cell lines with KRAS G12C mutation. 30”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,456
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 1×
“Hence, this phenomenon has historically been approached from a reductionist and gene-centric perspective ( 38 ).”
Background
Research works printed but not linked: 1
- C. Warden, Y. Yuan, X. Wu, Optimal calculation of RNA-seq fold-change values. Int. J. Comput. Bioinformatics In Silico Model 2, 285–292 (2013).
Cited by
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Zhou, C., Li, C., Luo, L., Li, X., Jia, K., He, N., Mao, S., Wang, W., Shao, C., Liu, X., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.001 · Cited by 102
Self-citationKRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 106
Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
Garg, P., Singhal, S., Kulkarni, P., Horne, D. A., Malhotra, J. D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144189 · Cited by 94
Self-citationPrecision Oncology: 2023 in Review
Murciano‐Goroff, Y. R., Suehnholz, S. P., Drilon, A. E. D. C., & Chakravarty, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1194 · Cited by 52
Metadata
- Authors
- Mohanty, A., Nam, A., Srivastava, S., Jones, J., Lomenick, B., Singhal, S. S., Guo, L., Cho, H., Li, A., Behal, A., Mirzapoiazova, T., Massarelli, E., Koczywas, M., Arvanitis, L. D., Walser, T., Villaflor, V., Hamilton, S., Mambetsariev, I., Sattler, M., Nasser, M. W., Jain, M., Batra, S. K., Soldi, R., Sharma, S., Fakih, M., Mohanty, S. K., Mainan, A., Wu, X., Chen, Y., He, Y., Chou, T.-F., Roy, S., Orban, J., Kulkarni, P., & Salgia, R.
- Affiliations
- City Of Hope National Medical Center (US)
- California Institute of Technology (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- University of Nebraska Medical Center (US)
- Translational Genomics Research Institute (US)
- Indian Institute of Science Education and Research Kolkata (IN)
- Institute for Bioscience and Biotechnology Research (US)
- Corresponding author
- Salgia, Ravi
- ORCID
- Mohanty, Atish
- Nam, Arin
- Srivastava, Saumya
- Jones, Jeff
- Lomenick, Brett
- Singhal, Sharad S.
- Guo, Linlin
- Cho, Hyejin
- Li, Aimin
- Mirzapoiazova, Tamara
- Massarelli, Erminia
- Koczywas, Marianna
- Arvanitis, Leonidas D.
- Walser, Tonya
- Villaflor, Victoria
- Hamilton, Stanley
- Mambetsariev, Isa
- Sattler, Martin
- Nasser, Mohd W.
- Jain, Maneesh
- Batra, Surinder K.
- Soldi, Raffaella
- Fakih, Marwan
- Mohanty, Saswat Kumar
- Mainan, Avijit
- Wu, Xiwei
- Chen, Yihong
- He, Yanan
- Chou, Tsui-Fen
- Roy, Susmita
- Orban, John
- Kulkarni, Prakash
- Salgia, Ravi
- Venue
- Science Advances
- Published
- 2023-10-13
- Volume
- 9
- Issue
- 41
- Pages
- eade3816-eade3816
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10575592
- OpenAlex
- W4387609462
- Cited by
- 79
- References
- 68
- Citations by year
- 2026: 26 · 2025: 31 · 2024: 20 · 2023: 2
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Department of Biotechnology, Ministry of Science and Technology, India (BT/12/IYBA/2019/12, BT/12/IYBA/2019)
- Department of Science and Technology, Ministry of Science and Technology, India
- National Institutes of Health
- Science and Engineering Research Board
- National Cancer Institute (R01CA218545, R01CA247471)
- National Institute of General Medical Sciences (R01GM141290)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS G12C, sotorasib, acquired drug resistance, non-small cell lung cancer, ITGB4, focal adhesions, Akt/mTOR signaling, Wnt/β-catenin signaling, carfilzomib, adagrasib, proteasome inhibitors, combination therapy
- MeSH terms
- Antiviral Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.